Abbreviated 510(k) review for devices subject to recalls planned by FDA.
This article was originally published in The Gray Sheet
Executive Summary
ABBREVIATED 510(k) REVIEW FOR DEVICES SUBJECT TO RECALLS is planned by FDA under an internal policy document being finalized at the agency's Center for Devices and Radiological Health. The policy will call for the device center's Office of Device Evaluation to complete within 30 days its review of 510(k)s submitted for changes made to devices as a result of a product recall, according to FDAers. The submissions currently are placed in the normal review queue.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.